I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Myelodysplastic syndrome (MDS) is a heterogenous group of hematopoietic stem cell disorders that are multifactorial in their etiology and often difficult to distinguish from hematological benign diseases with unilineage or multilineage cytopenia such as aplastic anemia (AA) both in clinic and laboratory. MDS is a heterogenous group of bone marrow (BM) clonal hematopoiesis with unilineage or multilineage dysplasia and cytogenetic abnormalities. However, all of these characterized manifestations are insufficient for an MDS diagnosis.\[[@ref1]\]

In a proportion of patients, hypoplastic MDS and MDS with a low blast count or a normal karyotype are difficult to distinguish from AA. In approximately 50% of patients with MDS, the BM shows a normal karyotype.\[[@ref2]\] In particular, only 12.5% of patients with hypoplastic MDS or MDS with a low blast count have chromosomal abnormalities.\[[@ref3]\] BM dyserythropoiesis and BM clone chromosomal abnormalities involving chromosomes 5, 7, and 8 have been seen in patients with MDS or AA.\[[@ref4]\] All these factors make it more difficult to distinguish MDS from AA.

Multiparameter flow cytometry (MFC) and molecular genetics were recently shown to be very helpful in MDS diagnostics. For MFC, a panel of frequently described phenotypic abnormalities in myeloid lineages in MDS has been performed in the clinical setting. Although no abnormal marker profile is specific for MDS, such phenotypic changes may help with the distinguishing of a normal or reactive BM from a clonal myeloid malignancy. However, MFC testing involves very strict requirements for BM specimens.\[[@ref5]\] The molecular abnormalities of MDS are less well-analyzed. Only some studies analyzed the occurrence of molecular markers that are typical for acute myeloid leukemia in MDS such as FLT3, RAS, and mixed lineage leukemia (MLL) and so on. It may be problematic to widely use applied molecular techniques for sample collection and preservation since they have a low coverage rate.\[[@ref6]\]

The initiation of MDS is believed to be a multistep process requiring gene expression abnormalities to accumulate malignant clone proliferation and differentiation inhibition. Gene expression abnormalities are believed to require the accumulation of both genetic and epigenetic alterations. The aberration of epigenetic regulation especial hypermethylation of tumor suppressor gene (TSG) promoter region plays a functionally equivalent role to genetic alterations in the gene silencing mechanism.\[[@ref7][@ref8][@ref9]\] In the past few years, the transcriptional inactivation of TSG by promoter CpG island hypermethylation has been a subject of intense interest as a causal factor in hematological malignancies.

One of the most frequently and best studied epigenetic events in MDS is the silencing of the cyclin-dependent kinase inhibitor gene *p15INKB*, which controls the progression of cells from the G1 to S phase.\[[@ref10]\] Hypermethylation of the *p15INKB* promoter region occurs in approximately 50% of MDS cases.\[[@ref11]\] It has been reported to be acquired during disease progression\[[@ref12][@ref13]\] and associated with leukemic transformation\[[@ref14]\] and poor prognosis. Yu *et al*.\[[@ref15]\] found that aberrant methylation of CpG islands of the *ID4* gene promoter region occurred in a T/NK acute lymphoblastic leukemia mouse model by restriction landmark genomic scanning. *ID4* gene aberrant hypermethylation has a relationship with the initial and development of many kinds of hematological malignant diseases. In addition, *ID4* is also involved in regulation of cell cycle, cell proliferation, and differentiation by several pathways such as aberrant hypermethylation of the promoter region.\[[@ref16][@ref17][@ref18][@ref19][@ref20][@ref21][@ref22][@ref23][@ref24][@ref25]\] A recent research showed a notable relationship of *ID4* gene methylation status with the initial and development of MDS.\[[@ref26]\]

To investigate the role of *ID4* gene aberrant methylation in the diagnosis of MDS, the methylation status of *ID4* was analyzed in patients with newly diagnosed MDS and AA by bisulfite sequencing polymerase chain reaction (PCR) (BSP) and MethyLight PCR. We studied the differences in *ID4* gene methylation statuses between patients with hypoplastic MDS and those with MDS and low blast counts or a normal karyotype with AA. We not only detected the occurrence of *ID4* methylation in patients with MDS or AA, but the methylation levels were also tested to make the initial accurate diagnosis. *ID4* gene methylation testing may be a new biomarker for the diagnosis of MDS.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Samples {#sec2-1}
-------

One hundred and thirty-one BM samples were obtained from adult patients diagnosed with different types of MDS (*n* = 100) or AA (*n* = 31). More detailed clinical information about the patients is presented in [Table 1](#T1){ref-type="table"}. Consent for sample collection was obtained from every patient who was enrolled in this study following institutional guidelines. Leukemia cell line NB4 and renal cell line 293 played positive and negative roles in our study, respectively.

###### 

Patients' clinical characteristics by group

  Groups                       Number of patients
  ---------------------------- --------------------
  AA                           31
   Karyotype abnormal          0/9
  MDS                          100
   WHO subtype                 
    RA                         41
    RARS                       7
    RCMD                       22
    RAEB1                      21
    RAEB2                      9
  Karyotype                    
   Abnormal                    18
   Normal                      19
  Low BM blast counts          47
  Hypoplastic BM cellularity   16

WHO: World Health Organization; AA: Aplastic anemia; MDS: Myelodysplastic syndrome; RA: Refractory anemia; RARS: Refractory anemia with ringed sideroblasts; RCMD: Refractory cytopenia with multilineage dysplasia; RCMD-RS: Refractory cytopenia with multilineage dysplasia and ringed sideroblasts; RAEB: Refractory anemia with excess of blasts; BM: Bone marrow, Karyotype abnormal, −5/5q−, −7/7q−, +8, 20q− and complex (≥3 abnormalities).

Genomic DNA extraction and bisulfite modification {#sec2-2}
-------------------------------------------------

Genomic DNA was extracted following the genomic DNA extraction kit (Promega, USA) guidelines. Next, 1 μg DNA was modified using an EpiTect Bisulfite kit (Qiagen, USA) according to the manufacturer\'s instructions. All of the unmethylated CpG sites of the DNA were converted to TG, while the methylated CpG sites remained CG. All of the bisulfite-treated DNA samples were stored at −20°C.

Detection of CpG site methylation frequency (bisulfite sequencing polymerase chain reaction) {#sec2-3}
--------------------------------------------------------------------------------------------

A bisulfite-treated *ID4* DNA sequence was used to design the primers. *ID4* primers \[[Table 2](#T2){ref-type="table"}\] were designed in promoter regions near the known transcription start sites. The forward primer sequence had no CpG site, while the reverse primer sequence had one CpG site. As such, the reverse primers were designed with a mixture of CG and CA to equally amplify the methylated and unmethylated sites. A final volume of 25 μl of the reaction mixture contained 0.5 μl of HotStarTaq (Qiagen), 20 pmol of each primer, 2.5 μl of × 10 Herman\'s PCR buffer, 1.25 μl of 25 mmol/L deoxynucleotide, and 2 μl of bisulfite-treated DNA. This PCR reaction consisted of 15 min of heating at 95°C, 40 PCR cycles of 50 s at 94°C, 45 s at 53°C, and 60 s at 72°C with a final 10 min at 72°C for elongation. The PCR product was a plasmid incorporated with *Escherichia coli* cells by the T4 ligase (Takara, China) and pGEM^®^-T Easy vector (Promega). Ten colonies were chosen for sequencing (Invitrogen).

###### 

Primer and probe sequences

  Genes                Forward                                Reverse
  -------------------- -------------------------------------- --------------------------------
  *ID4* BSP primer     GTTTGATTGGTTGGTTATTTTAGAT              ACCGAAAAAAAAATAACCCAC
                                                              CACCAAAAAAAAAATAACCCAC
  *ID4* methylight                                            
   Primer              TCGGAGTTTTCGTTTTCGTT                   CGATACTACTCACAACCGCG
   Probe               AGCGGGTTTCGTTCGGTTCG                   
  *MYOD1* methylight                                          
   Primer              CCAACTCCAAATCCCCTCTCTAT                TGATTAATTTAGATTGGGTTTAGAGAAGGA
   Probe               TCCCTTCCTATTCCTAAATCCAACCTAAATACCTCC   

BSP: Bisulfite sequencing polymerase chain reaction.

Quantitative detection of DNA methylation patterns by MethyLight {#sec2-4}
----------------------------------------------------------------

In our previous study, a complete MethyLight system for *ID4* methylation quantitative detection was established. This quantitative detection system had both high sensitivity and good specificity.\[[@ref27]\] We used MethyLight PCR to detect the DNA methylation status and determine the *ID4* gene methylation positivity rate and methylation level. The pairs of primers and the responding probe with 10 total CpG sites were designed according to the bisulfite-treated DNA sequence \[[Table 2](#T2){ref-type="table"}\]. The *MYOD1* gene, whose primers and probe described as prescribed, was chosen as the internal control gene to normalize for suitable amounts of bisulfite-treated DNA from every sample.\[[@ref28]\] All of the primers and probes that were labeled with FAM at the 5′ end and the quencher TAMRA at the 3′ end were synthesized by Invitrogen. The final reaction mixture consisted of 2.5 μmol of each primer, 1.25 μmol of probe, 2 μl of bisulfite-converted DNA, and TaqMan Universal PCR Master mix (Qiagen) according to the manufacturer\'s protocol. PCR was run under the following conditions: 95°C for 10 min, followed by 45 cycles at 95°C for 30 s, and 57°C for 1 min. MethyLight PCR was performed at M × 3000p (Stratagene) for the amplification and analyses.

CpG methylation was quantitated as follows: Fraction of methylated molecules = 100 × aim gene values/*MYOD1* gene values.

Statistical analyses {#sec2-5}
--------------------

The Mann-Whitney nonparametric test was performed to compare the scale measures. The Chi-square or Fisher\'s exact test was used to compare the categorical variables. All of the statistical analyses were performed using the Statistical Package for the Social Sciences version 18.0 for Windows (SPSS, Chicago, IL, USA). *P* \< 0.05 was considered significant, and all were two-tailed.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

*ID4* gene CpG site methylation frequency comparison between one patient with aplastic anemia and one patient with myelodysplastic syndrome using bisulfite sequencing polymerase chain reaction {#sec2-6}
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Bisulfite sequencing polymerase chain reaction was used to directly detect the methylation status of every CpG site of the given region. We analyzed the methylation status of BM samples of one patient with MDS and one patient with AA using Bisulfite sequencing polymerase chain reaction. For the *ID4* gene, every sample included 10 clones, each of which had 48 CpG sites. The *ID4* gene methylation positivity site frequency of the patients with MDS (29.38% \[141/480\]) was significantly higher than that of the patients with AA (8.125% \[39/480\]) (*P* = 0.000, [Figure 1](#F1){ref-type="fig"}).

![*ID4* genes CpG sites methylation frequencies between patients with aplastic anemia and those with myelodysplastic syndrome. ●: One positive CpG site (CG); ○: One negative CpG site (TG). TSS: Transcriptional start site; NBM: Normal bone marrow. The *ID4* gene methylation positivity site frequency in patients with myelodysplastic syndrome (29.38% \[141/480\]) was significantly higher than that of the patients with AA (8.125% \[39/480\]) (*P* = 0.000).](CMJ-128-2019-g001){#F1}

*ID4* gene promoter methylation status (by MethyLight) correlated with clinical characters in myelodysplastic syndrome and aplastic anemia patients {#sec2-7}
---------------------------------------------------------------------------------------------------------------------------------------------------

As summarized in [Table 3](#T3){ref-type="table"}, the MDS group had a higher *ID4* gene methylation positivity rate (*P* = 0.001) and higher methylation levels (*P* = 0.001) than the AA group. There were no significant differences in clinical features, such as gender, initial white blood cell counts, platelet counts, or the incidence of molecular genetic abnormalities between the MDS and AA groups (*P* \> 0.05). The proportion of initial hemoglobin level, age, and the incidence of chromosomal abnormalities were significantly different between the MDS and AA groups (*P* \< 0.05). However, these three factors did not differ between patients with *ID4* methylation and those with unimethylation (*P* \> 0.05). There was a significant difference in BM blast levels between patients with MDS and those with AA (*P* = 0.000) as well as between patients with MDS with or without hypermethylation (*P* = 0.001). In this study, 51.79% (29/56) of the patients with MDS harbored identical cytogenetic and molecular genetic markers (such as −5/5q−, −7/7q−, +8, 20q−, complex karyotype, N-RAS mutation, AML1 mutation, p53 mutation, EVI-1 overexpression, TEL fusions, MLL fusions) for distinguishing MDS. In the other 27 patients, the methylation positivity rate of the *ID4* gene was 22.22% (6/27). Therefore, 62.5% (35/56) of patients with MDS could be distinguished using a combination of genetic and epigenetic markers.

###### 

Comparison of clinical characteristics and methylation status between patients with aplastic anemia and those with MDS

  Indices                      AA                  MDS                 *P*
  ---------------------------- ------------------- ------------------- -------
  Patients (*n*)               31                  100                 
  Age (years)                  34.36 (12--71)      46.61 (13--86)      0.001
  Male/female (*n*)            20/11               55/45               0.349
  WBC (×10^9^/L)               3.88 (0.49--8.27)   4.12 (0.35--25.9)   0.130
  Hemoglobin (g/L)             100.5 (53--166)     86.17 (44--140)     0.036
  Platelet (×10^9^/L)          87.83 (1--307)      84.19 (1--459)      0.680
  BM blast (%)                 0.5 (0--1.6)        2.99 (0--17.2)      0.000
  Karyotype abnormal           0/9                 18/37               0.021
  Gene abnormal                0/9                 13/43               0.138
  *ID4* methylation                                                    
   Methylation positive rate   0/31                27/100              0.001
   Methylation level           0 (0--0)            0.21 (0--3.79)      0.001

MDS: Myelodysplastic syndrome; RA: Refractory anemia; RARS: Refractory anemia with ringed sideroblasts; RCMD: Refractory cytopenia with multilineage dysplasia; RCMD-RS: Refractory cytopenia with multilineage dysplasia and ringed sideroblasts; RAEB: Refractory anemia with excess of blasts; BM: Bone marrow; AA: Aplastic anemia; WBC: White blood cell counts; gene abnormal, N-RAS, FLT3, AML1, EVI-1, TEL, MLL, p53, IRF-1. Karyotype abnormal, −5/5q−, −7/7q−, +8, 20q− and complex (≥3 abnormalities).

*ID4* gene promoter methylation status (by MethyLight) in patients with hypoplastic myelodysplastic syndrome or myelodysplastic syndrome with low blast counts or normal karyotype {#sec2-8}
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The methylation positivity rates (*P* = 0.000) and methylation levels (*P* = 0.000) of the *ID4* gene were significantly different between patients with hypoplastic MDS and those with AA. The same results were found in patients with MDS and a normal karyotype and those with AA (*P* = 0.049, *P* = 0.024, [Table 4](#T4){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}). Between patients with MDS and a low BM blast count and patients with AA, only methylation levels (*P* = 0.040, [Table 4](#T4){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}) of the *ID4* gene had apparent differences, whereas *ID4* gene methylation positivity rates did not (*P* = 0.076, [Table 4](#T4){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}). Both patients with hypoplastic MDS and those with low BM blast counts showed differences in the abnormal karyotype from those of patients with AA (*P* = 0.014, *P* = 0.038, [Table 4](#T4){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}).

###### 

Comparison of clinical characteristics and methylation status among patients with aplastic anemia and those with hypoplastic MDS, those with MDS and a low BM blast count, and those with MDS and a normal karyotype

  Indices                      AA             Hypoplastic MDS   MDS with low BM blast counts   MDS with normal karyotype                                    
  ---------------------------- -------------- ----------------- ------------------------------ --------------------------- ------- ---------------- ------- --
  Patients (*n*)               31             16                                               47                                  19                       
  BM blast (%)                 0.5 (0--1.6)   4.9 (0--17.2)     0.000                          0.6 (0--1.8)                0.202   3.8 (0--17.2)    0.002   
  Karyotype                                                                                                                                                 
   Abnormal                    0/9            3/4               0.014                          9/19                        0.038   --               --      
  Gene                                                                                                                                                      
   Abnormal                    0/9            2/6               0.143                          6/23                        0.15    6/15             0.052   
  *ID4* methylation                                                                                                                                         
   Methylation positive rate   0/31           10/16             0.000                          6/47                        0.076   3/19             0.049   
   Methylation level           0 (0--0)       0.36 (0--2.8)     0.000                          0.39 (0--0.76)              0.040   0.15 (0--2.72)   0.024   

AA: Aplastic anemia; MDS: Myelodysplastic syndrome; BM: Bone marrow; gene abnormal, N-RAS, FLT3, AML1, EVI-1, TEL, MLL, p53, and IRF-1. Karyotype abnormal, −5/5q−, −7/7q−, +8, 20q− and complex (≥3 abnormalities).

![The *ID4* gene methylation distribution and levels of patients with aplastic anemia (AA) and myelodysplastic syndrome. (a) The *ID4* gene methylation distribution in patients with AA and those with myelodysplastic syndrome (MDS). In the patients with AA, no methylation abnormalities in the *ID4* gene were found; (b) *ID4* gene methylation level of patients with AA and MDS. The methylation positivity rates (*P* = 0.000) and methylation levels (*P* = 0.000) of the *ID4* gene were significantly different between patients with MDS and those with AA (0/31, 0 \[0--0\]).](CMJ-128-2019-g002){#F2}

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

Recently, epigenetic alterations, such as the aberrant methylation of CpG islands in the promoter regions of genes have been reported to inactivate TSG, and many genes were found to be silenced by methylation in solid tumors and hematological malignancies\[[@ref29]\] to contribute to tumor genesis,\[[@ref30]\] including MDS. Based on difficulty distinguishing MDS and hematological benign diseases such as AA that are only dependent on morphology and genetics, we turned to epigenetics, especially abnormal methylation of the TSG promoter region. Several studies have reported that the *P15* gene, which encodes a cyclin-dependent kinase inhibitor, is frequently methylated in patients with MDS but not in those with AA, which provides a key clue in the elucidation of *ID4* gene methylation status and levels to distinguish patients with hypoplastic MDS from those with MDS and low blast counts or a normal karyotype from those with AA. Because of the limited reports of the methylation status of *ID4* genes in MDS,\[[@ref26]\] especially regarding distinguishing MDS from AA, we were prompted to examine the genetics of patients with MDS and AA.

In our study, BSP revealed that the CpG sites of the *ID4* gene were more methylated in patients with MDS and refractory anemia than in those with AA. As the most direct technology for CpG site methylation status detection, BSP provides the most investible theoretic basis to further identify the different methylated status of the *ID4* gene.

This study demonstrated that both methylation positivity rates and methylation levels of the *ID4* gene were significantly higher in patients with MDS than in those with AA on MethyLight PCR, which was consistent with the results using BSP. A total of 27% of the patients with MDS had the higher methylation status of the *ID4* gene, whereas none of the patients with AA had the higher status. There was a strong correlation between BM blast level and *ID4* gene methylation (*P* = 0.001), and BM blast levels showed an obvious difference between patients with MDS and those with AA. Thus, to some extent, *ID4* gene methylation levels give clues to aid in the estimation of BM blast levels. The *ID4* methylation status may be independent of many clinical factors that are the genetic features of diseases. There were no significant differences in the incidence of molecular genetic abnormalities between patients with MDS and those with AA due to the lack of sufficient samples, so future studies with additional samples are necessary to confirm our findings. We estimated that there were no significant differences in the BM blasts in patients with MDS and low BM blast counts and those of AA patients; however, a significant difference in methylation levels was seen. Therefore, even in patients with low BM blasts, *ID4* gene methylation could help with the distinguishing of some patients with MDS from those with AA. Unfortunately, there was no significant difference in the *ID4* gene methylation positivity rate between patients with MDS and low BM blast counts and those with AA, which may also be due to the insufficient number of samples. However, our findings demonstrate the significance of the difference in *ID4* gene methylation levels between the two groups.

Approximately 50% of patients with MDS have no distinctive genetic markers (detected by cytogenetics or molecular genetics) for distinguishing them from patients with AA;\[[@ref2]\] thus, epigenetics, especially gene CpG site methylation, has become increasingly more popular and useful. Many studies have shown that the methylation positivity rates and the levels of many genes differed between patients with malignant diseases and those with normal bone marrow.\[[@ref8][@ref31][@ref32][@ref33][@ref34][@ref35]\] Few genes can currently be used for methylation detection to distinguish between MDS and AA. In this study, patients with MDS and a low BM blast count and those with MDS and a normal karyotype had significantly different abnormal karyotypes from those with AA. We found that patients with MDS had higher *ID4* gene methylation positivity rates and methylation levels than those with AA, and none of the 31 patients with AA had a positive methylation status. As such, detecting the *ID4* gene methylation status can distinguish a proportion of patients with MDS from those with AA in the absence of distinctive genetic markers, and many more patients with MDS could be correctly diagnosed using a combination of genetic and epigenetic markers.

Here, we reported the initial results of MDS diagnosis. Many more samples must be examined in a future study to confirm the role of this new marker and promote its application in the clinical setting. Our findings show that the combination use of genetic and epigenetic methods to improve the discriminability between MDS and AA.

In conclusion, this is the first study to examine the methylation status and levels of the *ID4* gene in patients with MDS and AA. A total of 27% of patients with MDS harbor the higher methylation status of the *ID4* gene compared to patients with AA, which provided the theoretical basis of the use of demethylating agents in patients with MDS, suggesting hypermethylation as a major causative agent in hematopoietic clonal disorders that can be used to distinguish MDS from AA.
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